Patrick Shiong
Director
ETUBICS CORPORATION
Romania
Biography
He invented and developed Abraxane, the nation’s first FDA-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe with sales of approximately $1.0 billion. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and an M.Sc. in science from the University of British Columbia. He is a board-certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada. He is an Adjunct Professor of Surgery at the University of California, Los Angeles, or UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health.
Research Interest
Oncology